Biogen (BIIB)
(Delayed Data from NSDQ)
$131.95 USD
+3.95 (3.09%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $131.93 -0.02 (-0.02%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth B Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Biogen Inc. has a PEG ratio of 1.70 compared to the Medical - Biomedical and Genetics industry's PEG ratio of 1.85.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BIIB 131.95 +3.95(3.09%)
Will BIIB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BIIB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BIIB
Biogen's Q2 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up
Biogen (BIIB) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
BIIB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ionis Beats on Q2 Earnings & Sales, Stock Up 5% on Raised '25 Outlook
Biogen Inc. (BIIB) Surpasses Q2 Earnings and Revenue Estimates
Biogen (BIIB) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Other News for BIIB
Earnings Scorecard: 18 out of 21 healthcare firms beat earnings forecast this week
Biogen: Strong Q2 Doesn't Change The Math On Eroding MS Portfolio
RBC Capital Boosts Biogen (BIIB) Price Target After Strong Q2 Earnings
RBC Capital Raises Price Target for Biogen (BIIB) to $219 | BIIB Stock News
Biogen (BIIB) Price Target Adjusted Amid Growth Concerns